Hungarian pharmaceutical company Gedeon Richter on Thursday said it entered into an exclusive licence agreement with UK-headquartered Hikma Pharmaceuticals to commercialise its drug denosumab, used to treat osteoporosis and fractures due to bone metastasis, in the United States.
Â
Denosumab comprises two biosimilar products referencing the brands Prolia and Xgeva.
Â
Under the agreement, Richter is responsible for the development of the products,
Â
conducting both Phase 1 and Phase 3 global clinical studies, and will supply the products for the US market.
Â
Hikma will be responsible for registering the products with the US Food and Drug Administration (FDA) and will have exclusive rights to commercialise them in the United States.
Â
Richter is eligible for an upfront payment and milestone payments totalling “a double-digit million USD figure” under the financial terms of the agreement.
Read alsoCNN wanted to spread fake news about Hungary? – VIDEO
If you would like to support the work of the Daily News Hungary staff and independent journalism,
please make a donation here
please make a donation here
Hot news
Did Orbán accidentally reveal the new Governor of the National Bank of Hungary?
Orbán promises to increase wages and family subsidies
Hungarian Defence Minister: ‘We have rearmed the air force in recent years’
How would the Airbnb ban affect Budapest’s rental market?
PM Orbán’s political director: ‘Hungary must represent a policy of economic neutrality’
PHOTOS: Hungary battles largest outdoor fire of the year, huge damage
